Table 2.
In vitro susceptibility of all and β-lactam-resistant phenotypes of P. aeruginosa collected by the SMART global surveillance programme from 2018 to 2020 in Western Europe
| Percentage of isolates susceptible (number of susceptible isolates in TZP- and MEM-resistant isolate subsets) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Phenotype/country/region (n) | IMR | IMPa | MEM | FEPa | CAZa | TZPa | LVXa | AMK |
| All isolates | ||||||||
| France (360) | 96.1 | 78.6 | 84.2 | 86.7 | 83.3 | 82.5 | 76.1 | 93.3 |
| Germany (282) | 96.8 | 69.5 | 73.4 | 84.4 | 78.7 | 78.0 | 70.2 | 96.8 |
| Italy (328) | 89.6 | 73.2 | 74.4 | 80.2 | 72.6 | 68.9 | 65.2 | 89.9 |
| Portugal (165) | 87.9 | 67.9 | 69.7 | 73.9 | 67.3 | 68.5 | 69.1 | 92.1 |
| Spain (494) | 89.3 | 67.8 | 69.4 | 75.5 | 72.7 | 70.5 | 54.5 | 92.3 |
| UK (366) | 88.8 | 75.7 | 77.3 | 77.6 | 73.8 | 75.7 | 68.6 | 85.5 |
| Western Europe (1995) | 91.4 | 72.3 | 74.9 | 79.8 | 75.2 | 74.2 | 66.2 | 91.5 |
| TZP-resistant isolates | ||||||||
| France (63) | 84.1 (53) | 49.2 (31) | 46.0 (29) | 38.1 (24) | 20.6 (13) | 0 (0) | 50.8 (32) | 81.0 (51) |
| Germany (62) | 91.9 (57) | 41.9 (26) | 38.7 (24) | 35.5 (22) | 11.3 (7) | 0 (0) | 56.5 (35) | 87.1 (54) |
| Italy (102) | 71.6 (73) | 46.1 (47) | 42.2 (43) | 39.2 (40) | 20.6 (21) | 0 (0) | 37.3 (38) | 70.6 (72) |
| Portugal (52) | 69.2 (36) | 32.7 (17) | 38.5 (20) | 25.0 (13) | 3.9 (2) | 0 (0) | 34.6 (18) | 80.8 (42) |
| Spain (146) | 71.2 (104) | 32.9 (48) | 29.5 (43) | 26.0 (38) | 18.5 (27) | 0 (0) | 19.2 (28) | 80.8 (118) |
| UK (89) | 61.8 (55) | 36.0 (32) | 34.8 (31) | 25.8 (23) | 13.5 (12) | 0 (0) | 36.0 (32) | 61.8 (55) |
| Western Europe (514) | 73.5 (378) | 39.1 (201) | 37.0 (190) | 31.1 (160) | 16.0 (82) | 0 (0) | 35.6 (183) | 76.3 (392) |
| MEM-resistant isolates | ||||||||
| France (20) | 55.0 (11) | 0.0 (0) | 0 (0) | 20.0 (4) | 35.0 (7) | 25.0 (5) | 10.0 (2) | 50.0 (10) |
| Germany (21) | 71.4 (15) | 9.5 (2) | 0 (0) | 28.6 (6) | 33.3 (7) | 23.8 (5) | 23.8 (5) | 76.2 (16) |
| Italy (49) | 40.8 (20) | 0.0 (0) | 0 (0) | 30.6 (15) | 22.5 (11) | 18.4 (9) | 8.2 (4) | 46.9 (23) |
| Portugal (21) | 33.3 (7) | 4.8 (1) | 0 (0) | 14.3 (3) | 9.5 (2) | 4.8 (1) | 9.5 (2) | 61.9 (13) |
| Spain (69) | 42.0 (29) | 5.8 (4) | 0 (0) | 17.4 (12) | 21.7 (15) | 17.4 (12) | 5.8 (4) | 75.4 (52) |
| UK (47) | 21.3 (10) | 0.0 (0) | 0 (0) | 8.5 (4) | 14.9 (7) | 12.8 (6) | 14.9 (7) | 42.6 (20) |
| Western Europe (227) | 40.5 (92) | 3.1 (7) | 0 (0) | 19.4 (44) | 21.6 (49) | 16.7 (38) | 10.6 (24) | 59.0 (134) |
IMR, imipenem/relebactam; IMP, imipenem; MEM, meropenem; FEP, cefepime; CAZ, ceftazidime; TZP, piperacillin/tazobactam; LVX, levofloxacin; AMK, amikacin.
a
The results represent % ‘susceptible, increased exposure’ (SIE).